30% of Swedish Newborns Are Missing a Critical Gut Bacteria, and It’s More Common Than Any Study Has Found Before

If you have ever wondered whether your infant's gut health is on the right track, a large Swedish study published in August 2026 in Gut Microbes offers a striking and somewhat unsettling data point: 30% of Swedish newborns in the study had no detectable Bifidobacterium in their gut during the first six months of life. That figure is higher than comparable national cohorts in the UK (20%) and the United States (25%), and it holds even among breastfed infants delivered vaginally, the two factors most strongly associated with healthy early microbial colonization.

Key takeaways:

• 30% of Swedish infants lacked Bifidobacterium in their first six months, higher than rates in UK or US cohorts.
• Infants without Bifidobacterium were more likely to have C-section births, longer hospital stays, and symptoms like excessive crying, nursing difficulties, and blood in stool.
• Their gut microbiomes instead harbored Clostridium and Klebsiella species, and lacked chemical signals linked to anti-inflammatory protection.
• Half of these infants remained Bifidobacterium-free for six months or more, suggesting this is not simply a temporary delay.
• This is emerging research; no specific intervention has been proven to correct the pattern, and parents should raise concerns with a pediatrician rather than act unilaterally.

Three Distinct Infant Gut Communities, One Worrying Gap

The PREVENT Study, which recruited 253 generally healthy, full-term Swedish infants through social media for broad geographic coverage, collected 744 stool samples at three-month intervals over the first year. Researchers performed deep metagenomic sequencing, reading the DNA directly from fecal samples to identify not just which bacteria were present, but what metabolic functions those communities were carrying out. From 200 samples collected in the first six months, three distinct gut community types emerged.

Community Type 1 (CT1), accounting for 57% of infants, was dominated by Bifidobacterium spp. (roughly 76% of total bacteria) and was associated with generally healthy outcomes. These infants more often had older siblings, a well-established proxy for early microbial exposure. Community Type 2 (CT2), seen in 17% of infants, had low Bifidobacterium (around 5%) but high Bacteroides (around 45%), and occurred almost exclusively in vaginally born infants. Community Type 3 (CT3), the most concerning group at 26% of infants, had almost no Bifidobacterium and instead harbored Clostridium neonatale, a potential opportunistic pathogen, and Klebsiella michiganensis, a species associated with hospital-acquired infections. CT3 infants were more likely to have been born by C-section (42% versus 19% in the Bifidobacterium-dominant group) and to have had long hospital stays.

Critically, the pattern was stable: half of the infants who lacked Bifidobacterium at their first sample remained without it for six months or longer. This is not a transient gap that resolves on its own.

Why Bifidobacterium Absence Matters for Immune and Metabolic Development

Bifidobacterium has a specialized role in the infant gut that goes well beyond simply being a beneficial microbe. It is one of very few organisms that can efficiently metabolize human milk oligosaccharides (HMOs), the complex sugars in breast milk that are otherwise indigestible by the infant. In doing so, it produces short-chain fatty acids and other metabolites that help structure the gut barrier and calibrate the immune system.

One of the more striking functional findings in the Swedish study was what happened chemically in the absence of Bifidobacterium. Infants in the Bifidobacterium-containing groups showed enrichment in enzymes that convert tryptophan (an amino acid) into indole-lactate (ILA) and indole-acetate (IAA), compounds associated with anti-inflammatory signaling. The enzyme most responsible, aromatic lactate dehydrogenase, came predominantly from B. longum, B. breve, and B. bifidum. Infants in CT3 lacked this biochemical capacity almost entirely.

Instead, CT3 infants showed elevated activity in pathways associated with mucus degradation, specifically enzymes that break down N-acetylglucosamine, a component of the gut lining. Elevated Ruminococcus gnavus, a bacterium linked to colicky symptoms in other research, was also highest in the no-Bifidobacterium group. A species called Thomasclavelia ramosa, also prevalent in CT3, has been correlated with childhood allergy in separate meta-analyses. Early-life gut dysbiosis has been linked to long-term risks including allergic disease, inflammatory bowel conditions, and metabolic disorders, though causality in those broader associations has not been established.

Separate research in US infants has found that a Bifidobacterium deficit significantly raises the risk of eczema, allergies, and asthma by age two, and there is growing concern that B. infantis is being lost across industrialized nations, possibly driven by antibiotic use, formula supplementation, and changing birth practices.

What the Symptoms in CT3 Infants Suggest

For parents, the clinical picture associated with CT3 is worth knowing, not as a diagnostic checklist, but as a set of signals worth raising with a pediatrician. Infants in the no-Bifidobacterium group more frequently showed nursing difficulties, excessive crying after feeding, and, in some cases, blood in stool. These symptoms can have many causes; the study does not establish that gut microbiome type was driving them. But the association is notable, and gut microbiota imbalances have been linked to allergic disease development in children in broader literature.

The finding that 58% of Bifidobacterium-absent infants were vaginally born is particularly important because it challenges the assumption that C-section alone explains poor microbial colonization. Vaginal birth does not guarantee a Bifidobacterium-rich gut. Breastfeeding, the presence of siblings, hospital stay length, and early antibiotic exposure all appear to matter independently.

What Remains Unproven, and What Comes Next

The PREVENT study has real limitations. The follow-up period was only one year, so whether the CT3 microbiome pattern translates into measurable health differences at age five or ten is genuinely unknown. The study did not collect data from national health registries or analyze breast milk composition, maternal microbiota, or the metabolites actually circulating in the infants' blood. These gaps matter because the metabolic enrichments described are based on predicted functional capacity from DNA, not directly measured metabolite levels.

No specific intervention was tested or recommended. Some early research suggests that supplementing infants with specific Bifidobacterium strains, such as B. longum subsp. infantis, may support Bifidobacterium-predominant colonization in term infants, but current guidelines note insufficient evidence to recommend probiotics for all neonates. That gap between a suggestive finding and a clinical recommendation is where this research currently sits.

The PREVENT team's next steps, though not detailed in the published paper, would logically involve linking microbiome data to health registry outcomes as participants age, and potentially examining whether early interventions in CT3 infants change the trajectory.

Common Questions

Should I be worried if my infant had a long hospital stay or C-section delivery? Those factors are associated with lower Bifidobacterium in this and other cohorts, but they are not destiny. Many C-section-born infants still develop Bifidobacterium-rich microbiomes. If you are concerned, it is worth discussing with your pediatrician, especially if your infant is also showing symptoms like excessive crying or nursing difficulties.

Does breastfeeding guarantee a healthy microbiome? Not automatically, according to this study. A significant proportion of breastfed, vaginally born Swedish infants still lacked Bifidobacterium. Breastfeeding clearly supports colonization, but other factors, including siblings, hospital environment, and antibiotic exposure, also shape the outcome.

Can probiotic supplements fix a Bifidobacterium deficit? Early research is suggestive but not conclusive. Some trials show that B. infantis supplementation can shift the microbiome toward Bifidobacterium dominance, but there is currently insufficient evidence to recommend it for all infants, and no supplement has been proven to prevent the downstream health risks hypothesized in this study. Ask your pediatrician before starting anything.

Is this finding specific to Sweden, or does it apply more broadly? Similar patterns have been reported in the UK and US, so this does not appear to be a uniquely Swedish phenomenon. The Swedish rate (30%) was the highest reported to date among comparable cohorts, which the authors attribute partly to recruitment methodology and possibly to broader lifestyle and healthcare factors in the Swedish context.

References

1. Eleonora Cavani, Alfons Edbom Devall, Yan Chen, et al. (2026). Nationwide cohort study reveals low bifidobacteria and distinct microbiota composition and function in Swedish newborns. Gut Microbes. https://doi.org/10.1080/19490976.2026.2719244
2. Gerrit A. Stuivenberg, Jeremy P. Burton, Peter A. Bron, Gregor Reid (2022). Why Are Bifidobacteria Important for Infants?. Microorganisms. https://doi.org/10.3390/microorganisms10020278
3. Alejandro Borrego-Ruiz, Juan J. Borrego (2025). Early-life gut microbiome development and its potential long-term impact on health outcomes. Microbiome Research Reports. https://doi.org/10.20517/mrr.2024.78
4. John B. Jarman, Pedro J. Torres, Sean Stromberg, et al. (2025). Bifidobacterium deficit in United States infants drives prevalent gut dysbiosis. Communications Biology. https://doi.org/10.1038/s42003-025-08274-7
5. Human milk oligosaccharides drive Bifidobacterium enrichment in the gut of breastfed infants. Science. https://www.science.org/doi/10.1126/science.abh2906
6. Relationship between Gut Microbiota and Allergies in Children: A Literature Review – PMC. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300139/
7. Akari Hiraku, Setsuko Nakata, Mai Murata, et al. (2023). Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial. Nutrients. https://doi.org/10.3390/nu15061402